10-QPeriod: Q2 FY2021

Medtronic plc Quarterly Report for Q2 Ended Oct 30, 2020

Filed December 3, 2020For Securities:MDT

Summary

Medtronic plc reported net sales of $7.65 billion for the third quarter ended October 30, 2020, a slight decrease of 0.8% compared to the prior year quarter, largely due to the ongoing impacts of the COVID-19 pandemic. For the first six months of fiscal year 2021, net sales were $14.15 billion, down 6.9% year-over-year. Diluted earnings per share (EPS) for the quarter were $0.36, down significantly from $1.01 in the prior year, reflecting lower revenue and increased operating expenses. The company's financial performance continues to be influenced by the global pandemic, with a notable impact on procedural volumes across its various business segments. Despite the revenue decline, Medtronic demonstrated operational resilience. The company reported strong growth in certain areas, such as ventilators within the Minimally Invasive Therapies Group, driven by COVID-19 demand. However, other segments like Cardiac & Vascular Group and Restorative Therapies Group experienced declines due to deferred procedures. The company has initiated restructuring programs, 'Enterprise Excellence' and 'Simplification,' aiming for future efficiencies and cost savings. Medtronic maintained a strong liquidity position, with substantial cash and investments, and continued to focus on strategic capital allocation.

Financial Highlights

54 data points
Beta

Revenue

$7.65B

64.6% Gross Margin

Net Income

$494.00M

6.5% Net Margin

EPS (Diluted)

$0.36

Total Assets

$95.89B

Cash & Equivalents

$6.42B

Free Cash Flow

$1.58B

Financial Statements
Beta
Revenue$7.65B
Cost of Revenue$2.71B
Gross Profit$4.94B
SG&A Expenses$2.60B
Operating Income$930.00M
Interest Expense$470.00M
Net Income$494.00M
EPS (Basic)$0.36
EPS (Diluted)$0.36
Shares Outstanding (Basic)1.34B
Shares Outstanding (Diluted)1.35B

Key Highlights

  • 1Q3 FY2021 net sales of $7.65 billion, a slight decrease of 0.8% year-over-year, impacted by COVID-19.
  • 2First six months FY2021 net sales decreased by 6.9% to $14.15 billion.
  • 3Diluted EPS of $0.36 for Q3 FY2021, a significant decrease from $1.01 in Q3 FY2020.
  • 4Minimally Invasive Therapies Group saw growth driven by increased demand for COVID-19 related diagnostics and therapies, especially ventilators.
  • 5Cardiac & Vascular Group and Restorative Therapies Group experienced sales declines due to reduced procedural volumes from the pandemic.
  • 6Company initiated 'Simplification' restructuring program to improve agility and accelerate decision-making, with estimated costs of $400-$450 million.
  • 7Strong liquidity position maintained with $6.4 billion in cash and cash equivalents and $7.9 billion in investments as of October 30, 2020.

Frequently Asked Questions

The primary driver behind the sales decline was the ongoing impact of the COVID-19 pandemic, which led to reduced medical procedure volumes across many of Medtronic's segments. This was partially offset by increased demand for certain products, such as ventilators.

Medtronic is focusing on operational efficiency and future growth through restructuring programs like 'Enterprise Excellence' and the newly initiated 'Simplification' program. These initiatives aim to streamline operations, reduce costs, and improve agility. The company is also strategically managing its product portfolio, focusing on areas with high demand and recovering deferred procedures.

Medtronic maintains a strong liquidity position. As of October 30, 2020, the company had $6.4 billion in cash and cash equivalents and $7.9 billion in investments. Additionally, it has an undrawn $3.5 billion credit facility. Management believes this liquidity is sufficient to meet its foreseeable operating needs for at least the next 12 months.

The company incurred significant restructuring charges in the current period. For the three months ended October 30, 2020, restructuring charges were $102 million, primarily related to employee termination benefits and associated costs for the new 'Simplification' program. These charges, along with other non-GAAP adjustments, impacted the reported net income and diluted EPS.